These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36546178)

  • 21. Mitochondrial DNA mutation correlates with stage progression and prognosis in non-small cell lung cancer.
    Matsuyama W; Nakagawa M; Wakimoto J; Hirotsu Y; Kawabata M; Osame M
    Hum Mutat; 2003 Apr; 21(4):441-3. PubMed ID: 12655558
    [No Abstract]   [Full Text] [Related]  

  • 22. [Association of molecular biology of lung cancers and their metastasis and prognosis].
    Mao YS; Gao YN; He J
    Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):632-4. PubMed ID: 17236563
    [No Abstract]   [Full Text] [Related]  

  • 23. Vascular endothelial growth factor polymorphisms in early-stage non-small-cell lung cancer.
    Patel M; Ailawadhi S; Hernandez-Ilizaliturri F; Wilding GE
    J Clin Oncol; 2008 Jul; 26(19):3289-90; author reply 3290. PubMed ID: 18591568
    [No Abstract]   [Full Text] [Related]  

  • 24. First clinically useful marker for lung cancer identified.
    Oncology (Williston Park); 2003 May; 17(5):737-8. PubMed ID: 12800797
    [No Abstract]   [Full Text] [Related]  

  • 25. DNA flow cytometric analysis in patients with operable non-small cell lung carcinoma.
    Granone P; Cardillo G; Rumi E; D'Ugo D; Rumi C; Ciletti S; Margaritora S; Terribile D; Picciocchi A
    Eur J Cardiothorac Surg; 1993; 7(7):351-5. PubMed ID: 8396951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum sMICA as biomarker in detection of non-small-cell lung carcinoma.
    Xing S; Zhu Y; Sun Y
    Br J Biomed Sci; 2018 Jan; 75(1):50-52. PubMed ID: 29182468
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical significance of marrow micrometastases on outcome in operable non-small-cell lung cancer.
    Hodge A; Sturm M; Shaw K
    ANZ J Surg; 2006 Aug; 76(8):765. PubMed ID: 16916406
    [No Abstract]   [Full Text] [Related]  

  • 28. Current concepts in the staging of non-small cell lung cancer.
    Grondin SC; Liptay MJ
    Surg Oncol; 2002 Dec; 11(4):181-90. PubMed ID: 12450554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation and treatment of patients with non-small cell lung cancer.
    Carr LL; Finigan JH; Kern JA
    Med Clin North Am; 2011 Nov; 95(6):1041-54. PubMed ID: 22032426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.
    Reck M; Rabe KF
    N Engl J Med; 2017 Aug; 377(9):849-861. PubMed ID: 28854088
    [No Abstract]   [Full Text] [Related]  

  • 31. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients.
    Kaduthanam S; Gade S; Meister M; Brase JC; Johannes M; Dienemann H; Warth A; Schnabel PA; Herth FJ; Sültmann H; Muley T; Kuner R
    Lung Cancer; 2013 May; 80(2):223-7. PubMed ID: 23410826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.
    Kann BH; Verma V; Stahl JM; Ross R; Dosoretz AP; Shafman TD; Gross CP; Park HS; Yu JB; Decker RH
    Radiother Oncol; 2019 May; 134():44-49. PubMed ID: 31005223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preliminary study on thymidine labelling index in human non-small cell lung cancer.
    Saccani Jotti GM; Gabrielli M; Orsi N; Fontanesi M; Sansebastiano G; Rusca M
    Int J Biol Markers; 1995; 10(2):122-3. PubMed ID: 7561239
    [No Abstract]   [Full Text] [Related]  

  • 34. Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients.
    Tibaldi C; Giovannetti E; Vasile E; Boldrini L; Gallegos-Ruiz MI; Bernardini I; Incensati R; Danesi R; Cappuzzo F; Peters GJ; Fontanini G
    J Thorac Oncol; 2011 Feb; 6(2):395-6. PubMed ID: 21252721
    [No Abstract]   [Full Text] [Related]  

  • 35. Testing New Neoadjuvant Combos in NSCLC.
    Cancer Discov; 2022 Jun; 12(6):1400-1401. PubMed ID: 35413108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Stereotactic Ablative Radiotherapy for Operable Stage I Non-small Cell Lung Cancer in Clinical Practice: How Long Way to Go?].
    Fu X; Cai X
    Zhongguo Fei Ai Za Zhi; 2015 Jul; 18(7):401-2. PubMed ID: 26182863
    [No Abstract]   [Full Text] [Related]  

  • 37. Should pleural fluid cytology be incorporated in the TNM staging system for operable nonsmall cell lung cancer?
    Pramesh CS; Mistry RC; Agarwal J; Bishnoi R
    Ann Thorac Surg; 2006 Dec; 82(6):2338-9; author reply 2339-40. PubMed ID: 17126174
    [No Abstract]   [Full Text] [Related]  

  • 38. Surgery versus stereotactic body radiation therapy for operable stage I non-small cell lung cancer: Can we achieve equipoise?
    Onaitis MW; Salama J
    J Thorac Cardiovasc Surg; 2016 Jul; 152(1):1-2. PubMed ID: 27343902
    [No Abstract]   [Full Text] [Related]  

  • 39. Update in the treatment and molecular biology of non-small cell lung cancer.
    Erlich R; Levitt ML
    Compr Ther; 1995 Aug; 21(8):445-57. PubMed ID: 8536445
    [No Abstract]   [Full Text] [Related]  

  • 40. P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer.
    Costa A; Silvestrini R; Mochen C; Lequaglie C; Boracchi P; Faranda A; Vessecchia G; Ravasi G
    Br J Cancer; 1996 Apr; 73(7):914-9. PubMed ID: 8611406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.